



Canadian Cancer Society
Société canadienne du cancer

Canadian Cancer Society proudly presents

O. Harold Warwick Prize

The O. Harold Warwick Prize is given to a scientist whose research has had a major impact on cancer control in Canada.

The prize is named after Dr Warwick, a pioneering researcher in cancer control and treatment,

who became the first executive director of both the former National Cancer Institute of Canada and the Canadian Cancer Society.

Dr William Foulkes

2013

Dr William Foulkes is internationally recognized for his contributions to our understanding of cancer genetics, in particular in hereditary breast and ovarian cancers. He was one of the first to show that most BRCA1-related tumours are estrogen receptor negative and the first to publish on the impact of BRCA1 mutations in breast cancer outcomes. Two of his publications describing the clinical and pathological features of BRCA1-related breast cancers are considered key in the field and have been cited over 600 times.

More recently, Dr Foulkes identified the first mutation in the DICER1 gene that connected multi-nodular goitre to a rare type of ovarian cancer. He is a world leader in researching and detailing the syndrome resulting from these mutations. Dr Foulkes has also identified genetic mutations in a breast cancer susceptibility gene called PALB2 and mutations responsible for inherited susceptibility to stomach, intestinal and uterine cancers. Most recently, he led an international team that identified a gene for small cell carcinoma of the ovary.

Dr Foulkes is a Professor in the Departments of Medicine, Human Genetics and Oncology at McGill University and the Director of McGill's Program in Cancer Genetics.

He is an author on almost 400 publications, 40 of which are commentaries or invited editorials in prestigious medical journals.

Dr Foulkes actively seeks to bring his research findings to the clinic and clinical experience to research.

For example, he helped develop tests making breast and colon cancer gene screening available to Quebec women at increased cancer risk. In 2005, he established an international scientific symposium on hereditary breast and ovarian cancers, which has included a day dedicated to the needs of mutation carriers and their families.

Among his honours is an appointment as a Komen Scholar in 2010, one of two Canadians chosen to serve on the Scientific Advisory Council of Susan G. Komen.

Marc Gosselin
Chair

Pamela C. Fralick
President & CEO

Christine Williams
Vice-President, Research